Spotlight on 4‐substituted quinolines as potential anti‐infective agents: Journey beyond chloroquine. Issue 3 (9th December 2022)

• Record Type: Journal Article
• Authors: Goyal, Ankush; Kharkwal, Harsha; Piplani, Mona; Singh, Yogendra; Murugesan, Sankaranarayanan; Aggarwal, Amit; Kumar, Piyush; Chander, Subhash
• Is Part Of: Archiv der Pharmazie. Volume 356:Issue 3(2023)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-12-09
• Subjects: antiviral activity -- heterocyclic -- resistance -- selectivity -- structure–activity relationship; Pharmaceutical chemistry -- Periodicals; Pharmacology -- Periodicals; 615.19
• DOI: 10.1002/ardp.202200361
• Languages: English
• ISSNs: 0365-6233

Abstract

Abstract: Continued emerging resistance of pathogens against the clinically approved candidates and their associated limitations continuously demand newer agents having better potency with a more suited safety profile. Quinoline nuclei containing scaffolds of natural and synthetic origin have been documented for diverse types of pharmacological activities, and a number of drugs are clinically approved. In the present review, we unprecedentedly covered the biological potential of 4‐substituted quinoline and elaborated a rationale for its special privilege to afford the significant number of approved clinical drugs, particularly against infectious pathogens. Compounds with 4‐substituted quinoline are well documented for antimalarial activity, but in the last two decades, they have been extensively explored for activity against cancer, tuberculosis, and several other pathogens including viruses, bacteria, fungi, and other infectious pathogens. In the present study, the anti‐infective spectrum of this scaffold is discussed against viruses, mycobacteria, malarial parasites, and fungal and bacterial strains, along with recent updates in this area, with special emphasis on the structure–activity relationship. Abstract : This review covers the biological potential of 4‐substituted quinoline and gives a rationale for its special privilege to afford many approved clinical drugs, particularly against infectious pathogens. The anti‐infection spectrum of these compounds against viruses, mycobacteria, malarial parasites, and fungal and bacterial strains is discussed, along with recent updates in this area, with special emphasis on the structure–activity relationship.